Postoperative survival estimated by Kaplan-Meier method and Log-rank test in 214 oligodendroglial tumors.

<p>Postoperative survival estimated by Kaplan-Meier method and Log-rank test in 214 oligodendroglial tumors.</p

Distribution of molecular markers in the entire study sample of 214 oligodendroglial tumors.

<p>Distribution of molecular markers in the entire study sample of 214 oligodendroglial tumors.</p

Cox regression model for postoperative survival in the entire cohort of 214 oligodendroglial tumors.

<p>Cox regression model for postoperative survival in the entire cohort of 214 oligodendroglial tumors.</p

Postoperative survival in IDHmut-codel oligodendrogliomas compared to oligodendroglial tumors with unknown or incomplete molecular profile, NOS.

<p>Red circle: IDHmut-codel oligodendrogliomas. Black circle: oligodendroglial tumors with unknown or incomplete molecular profile, NOS. Censored (still alive) patients are indicated by + and dead patients by o.</p

Distribution of clinical features for 1p19q codeleted oligodendrogliomas compared to oligodendroglial tumors with unknown or incomplete molecular profile.

<p>Distribution of clinical features for 1p19q codeleted oligodendrogliomas compared to oligodendroglial tumors with unknown or incomplete molecular profile.</p

CXCL12 and CXCR4 expression in mouse RCAS-<i>KRas</i>+RCAS-<i>Akt</i> induced gliomas.

<p>Immunofluorescence staining for CXCL12 and CXCR4 was performed in both <i>Ntv-a Arf−/−</i> and <i>Gtv-a Arf−/−</i> mouse gliomas. The quantification of intensity signal for CXCL12 (lower left panel) and CXCR4 (lower right panel) revealed statistically significant difference between tumor and nontumor areas of the objective fields in both <i>Ntv-a Arf−/−</i> and <i>Gtv-a Arf−/−</i> mouse brain tumors (* p<0.05). Error bars show SD. Scale bar = 50 µM.</p

Summary of patient characteristics and treatment received.

<p>OII = oligodendroglioma grade II, AII = astrocytoma grade II, Primary GBM = primary glioblastoma, F = female, M = male.</p

MC infiltration of human gliomas.

<p>(<b>A</b>) Immunohistochemical analysis of human MC tryptase (hTRS) in human low-grade gliomas (grade II, n = 8) and glioblastomas multiforme (GBM) (grade IV, n = 10). Right panel: quantification of MCs. Error bars show SD, *** p<0.001. Scale bar = 50 µM. (<b>B</b>) Immunofluorescence staining for CXCL12 and CXCR4 in human GBMs. Scale bar = 50 µM. (<b>C</b>) Immunofluorescence staining for CXCR4 and hTPS in human GBMs displayed co-expression of CXCR4 and hTPS. Scale bar = 25 µM. The inset represents a MC with co-localization of CXCR4 and hTPS at the single-cell level where maximum intensity projection of z-stack confocal images was applied.</p

Illustration of the immunohistochemistry results in astrocytomas grade II (n = 42), and in oligodendrogliomas (n = 27) plus oligoastrocytomas grade II (n = 18).

<p>Positive immunoreactivity for each of the four different GABA-A channel subunits is visualized by a colored bar. Each number represents one tumor sample.</p

Photomicrographs of an oligodendroglioma grade II showing positive immunoreactivity for: A) GABA-A channel α1 subunit, and B) γ1 subunit.

<p>The histological markers used for identification of specific cell types, CD34, IDH1, Ki67 and neuronal nuclear antigen (NeuN) illustrate respectively, C) haematopoetic cells in the tumor, D) accumulation of mutated IDH1 protein in tumor cells, E) a low percentage of proliferating tumor cells, F) an entrapped neuron in the tumor. (The scale bar shown in A represents 50 µm in A, B, F; 80 µm in C, D, E).</p